Shares of Biogen Idec
(NASDAQ:BIIB) jumped Wednesday after the company said
that it’s buying partner Elan’s
(NYSE:ELN) interest in the multiple sclerosis drug Tysabri for $3.25 billion.
Biogen will pay cash and agreed to additional royalty payments (up to 25%) on the drug’s sales to gain the 50% of profit that Elan now collects from Tysabri. Biogen says the purchase will add as much $.30 to earnings per share in 2013.
Biogen’s stock rose more than 3% in late morning trading to $162.70 after jumping 6% earlier Wednesday. The stock is up by a third over the past 12 months. The US shares of Irish drug maker Elan dropped 8% to $9.60. That stock is down by 30% over the past year.
While Biogen appears to be the winner in this deal, the transaction may seem like a head scratcher to some investors. Wall Street analysts see Biogen’s near- and long-term future tied to an experimental pill for multiple sclerosis, Tecfidera, that will be more convenient than injected treatments like Tysabri. Approved in the US in 2004, Tysabri was a drug plagued by safety concerns early in its launch. And Biogen is paying a full price for an older drug in a competitive therapy area.
Still, Biogen CEO George Scangos calls the move “a natural next step for us.” On a call with analysts Wednesday morning, Scangos says he sees future growth from the drug and Biogen will benefit from full ownership. Tysabri is a highly effective treatment for multiple sclerosis and Scangos hopes to broaden its use in patients with the disease. He also sees potential for testing the drug for other conditions, including stroke. Admitting the “early challenges” for Tysabri, Scangos called the product a very important therapy in a critical treatment area for Biogen.
Tysabri was taken off the market in 2005 because of its link to a rare and fatal brain disease. It was allowed back on the market the following year under a restricted distribution agreement with the US government. Last year, the Food and Drug Administration approved
a test that screens for risk of the rare brain infection and allowed the Tysabri label to warn people testing positive for such a risk not to use the drug.
Multiple sclerosis is Biogen’s core strategic focus. Tysabri’s sales were $1.6 billion last year, with more than half the revenue coming from the US. Sales of another Biogen drug for multiple sclerosis, Avonex, were $2.9 billion last year. And analysts have high hopes for Tecfidera, an oral treatment that would compete with Novartis’
(NYSE:NVS) Gilenya if approved. The FDA is scheduled to make a decision by the end of March on Tecfidera.
Asked if the purchase of Elan’s interest in Tysabri reflected waning confidence in the new oral drug, Tecfidera, Scangos said it did not.
“That’s in the category of a 'no good deed goes unpunished' question,” he said. “We have a really nice deal here for Tysabri. It has nothing to do -- zero -- with Tecfidera ... it can only benefit the other drugs in our portfolio. Don’t take our confidence in Tysabri as a lack of confidence in anything else in our portfolio.”
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.